Adaptimmune Therapeutics PLC — Director's Dealing 2022

Jan 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-01-12

Reporting Person: Rawcliffe Adrian (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-12	Option to purchase Ordinary Shares	$0.60	A	4690224	Acquired	2032-01-12	Ordinary Shares (4690224)	Direct
2022-01-12	Option to purchase Ordinary Shares	$0.0014	A	1047480	Acquired		Ordinary Shares (1047480)	Direct

Footnotes

F1: The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.